Adherex Technologies, Inc. (AMEX: ADH), a biopharmaceutical company, is focused on discovering and developing novel cancer therapeutics. They currently have a number of products in the clinical stage of development, including eniluracil, ADH-1 and sodium thiosulfate (STS). Adherex’s mission is to become a leading developer of innovative treatments that address important unmet medical needs in cancer. For further information, visit the Company’s web site at www.adherex.com.
- 17 years ago
QualityStocks
Adherex Technologies, Inc. (AMEX: ADH)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Black Hawk Acquisition Corporation (Nasdaq: BKHA) SPAC Target Vesicor Therapeutics Names Michael Tolentino CEO
Black Hawk Acquisition (Nasdaq: BKHA, BKHAU, BKHAR) announced that its proposed de-SPAC acquisition target, Vesicor Therapeutics Inc., has…
-
Renewal Fuels Inc. (RNWF) Discusses Ambitious Fusion Reactor Plan, Business Model and Strategy, on Stock2Me Podcast
The company aims to deliver a 100-megawatt fusion reactor in 2026, with an earlier 5-MW…
-
Navigating a Rapidly Evolving Technology Landscape: Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) and the Trump Administration’s Push to Secure Domestic Supplies of Critical Minerals
Disseminated on behalf of Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) and may include…